Grifols: Immunologic Deficiency Syndromes trials
The registry lists 10 Immunologic Deficiency Syndromes studies with Grifols as lead sponsor. 0 are open to participants now and 8 have results posted.
Phase 2 1Phase 3 6Phase 4 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary ImmunodeficiencyCompletedNCT04566692Phase 4Results posted
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral ImmunodeficiencyCompletedNCT04561115Phase 3Results posted
- Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PIDCompletedNCT02810444Phase 3Results posted
- Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary ImmunodeficiencyCompletedNCT02806986Phase 3Results posted
- Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary ImmunodeficiencyCompletedNCT02604810Phase 3Results posted
- Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary ImmunodeficiencyCompletedNCT01465958Phase 4Results posted
- Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric SubjectsCompletedNCT00634569Phase 4Results posted
- A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary ImmunodeficiencyCompletedNCT00389324Phase 2Results posted
- Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary ImmunodeficiencyWithdrawnNCT03814798Phase 3
- Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency PatientsCompletedNCT00220766Phase 3